• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
No Result
View All Result
Home Lifestyle Health

Vaccine that protects children against malaria is one step closer

Parasite will never develop resistance to the vaccine which could spell the end of the deadly disease.

Joe Mellor by Joe Mellor
2018-07-13 10:22
in Health, News, Science
FacebookTwitterLinkedinEmailWhatsapp

A vaccine that protects children against malaria by arming their body’s defences system so they can fight off their first infection is one step closer.

The breakthrough in mice experiments works by targeting the specific protein that parasites use to evade the immune system.

Now Yale University scientists are hoping to develop a human vaccine for young children who never have been infected by the disease so they have an immune response.

And the parasite will never develop resistance to the vaccine which could spell the end of the deadly disease.

Malaria is the second leading cause of infectious disease worldwide.

The 2014 World Malaria Report, published by the World Health Organisation (WHO), estimates there were 198 million cases of malaria worldwide and 584,000 deaths in 2013.

While malaria is not found in the UK, 1,586 travellers were diagnosed with the disease after returning to the UK in 2014, and three people died.

RelatedPosts

No swiping left! A new conservative dating app is being lampooned on-line

Enough is Enough: Campaign group say ‘billionaires need us, we don’t need them’

Energy bills: Campaign Don’t Pay gains momentum as it hits supporter milestone

Price cap predictions hiked again as Liz Truss slams windfall taxes

The effects of malaria are usually more severe in pregnant women, babies, young children and the elderly.

Symptoms include a fever, sweats and chills, headaches, vomiting, muscle pains and diarrhoea and if not diagnosed and treated promptly, it can be fatal.

The tropical disease is spread by mosquitoes infected with a parasite known as Plasmodium which passes into the bloodstream when you get bitten.

Until now there has not been completely effective vaccine and infected individuals only develop partial immunity against disease symptoms.

In previous studies Professor of medicine Dr Richard Bucala identified a unique protein produced by malaria parasites, Plasmodium macrophage migration inhibitory factor (PMIF).

This suppresses memory T cells, the infection-fighting cells that respond to threats and protect the body against reinfection.

In the new study Prof Bucala and his co-authors collaborated with Novartis Vaccines, Inc. to test an RNA-based vaccine designed to target PMIF.

First, using a strain of the malaria parasite with PMIF genetically deleted, they observed that mice infected with that strain developed memory T cells and showed stronger anti-parasite immunity.

Next, the research team used two mouse models of malaria to test the effectiveness of a vaccine using PMIF.

One model had early-stage liver infection from parasites carried by mosquitoes, and the other, a severe, late-stage blood infection. In both models, the vaccine protected against reinfection.

As a final test, the researchers transferred memory T cells from the immunised mice to “naïve” mice never exposed to malaria. Those mice were also protected.

The study found PMIF was critical to the completion of the parasite life cycle because it ensures transmission to new hosts, and also demonstrated the effectiveness of the anti-PMIF vaccine.

Prof Bucala added: “If you vaccinate with this specific protein used by the malaria parasite to evade an immune response, you can elicit protection against re-infection.

“To our knowledge, this has never been shown using a single antigen in fulminant blood-stage infection.”

The next step is to develop a vaccine for individuals who have never had malaria, primarily young children.

He said: “The vaccine would be used in children so that they would already have an immune response to this particular malaria product, and when they became infected with malaria, they would have a normal T cell response, clear the parasite, and be protected from future infection.”

Because the PMIF protein has been conserved by evolution in different malaria strains and targets a host pathway, it would be virtually impossible for the parasite to develop resistance to this vaccine.

Numerous other parasitic pathogens also produce MIF-like protein which suggested this approach may be generalisable to other parasitic diseases such as Leishmaniasis, Hookworm, and Filariais for which no vaccines exist.

The study was published by Nature Communications.

 

Since you are here

Since you are here, we wanted to ask for your help.

Journalism in Britain is under threat. The government is becoming increasingly authoritarian and our media is run by a handful of billionaires, most of whom reside overseas and all of them have strong political allegiances and financial motivations.

Our mission is to hold the powerful to account. It is vital that free media is allowed to exist to expose hypocrisy, corruption, wrongdoing and abuse of power. But we can't do it without you.

If you can afford to contribute a small donation to the site it will help us to continue our work in the best interests of the public. We only ask you to donate what you can afford, with an option to cancel your subscription at any point.

To donate or subscribe to The London Economic, click here.

The TLE shop is also now open, with all profits going to supporting our work.

The shop can be found here.

You can also SUBSCRIBE TO OUR NEWSLETTER .

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Watch: Downton’s Dan Stevens discusses PM’s takedown on The One Show

Workers laid off as PPE contracts handed to firms connected to Conservative party buying kit from abroad

Lost Property Celebrates Dada Centenary @ Cafe Oto

Bake Off returns with hilarious Prime Ministerial address from Matt Lucas

Police rake in £1.7million flogging designer bling seized from criminals on eBay

Creating A New E-Commerce Strategy With An SEO Agency

Watch – Baby turtles ‘almost four times as likely to die from eating plastic than adults’

TLE meets…comedian Phil Nichol

Councillor dubbed ‘Disappearing Donald’ after moving 400 miles from his constituency in Cambridge

‘Project Fear’ trends as Express bemoans Brexit airport queues

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.